Active Not Recruiting PHASE4 INTERVENTIONAL 1-arm NCT03229200

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.

Sponsor: Janssen Biotech, Inc., including Johnson & Johnson

Conditions Graft Vs Host Disease Leukemia, B-cell Lymphoma, B-Cell Lymphoma, Non-Hodgkin Solid Tumor

Interventions Ibrutinib

Updated 35 times since 2017 Last updated: Oct 28, 2025 Started: May 22, 2017 Primary completion: May 10, 2027 Completion: May 10, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Graft Vs Host Disease and Leukemia, B-cell and is currently ongoing. Janssen Biotech, Inc., including Johnson & Johnson leads this study, which shows 35 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

35 versions recorded

Nov 2025 — Present [monthly]

Active Not Recruiting PHASE4

Status: Enrolling By Invitation → Active Not Recruiting
Sep 2025 — Nov 2025 [monthly]

Enrolling By Invitation PHASE4
Sep 2024 — Sep 2025 [monthly]

Enrolling By Invitation PHASE4
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation PHASE4
Dec 2023 — Jul 2024 [monthly]

Enrolling By Invitation PHASE4

▶ Show 30 earlier versions

Dec 2022 — Dec 2023 [monthly]

Enrolling By Invitation PHASE4
Nov 2022 — Dec 2022 [monthly]

Enrolling By Invitation PHASE4
May 2022 — Nov 2022 [monthly]

Enrolling By Invitation PHASE4
Oct 2021 — May 2022 [monthly]

Enrolling By Invitation PHASE4
Sep 2021 — Oct 2021 [monthly]

Enrolling By Invitation PHASE4
Jun 2021 — Sep 2021 [monthly]

Enrolling By Invitation PHASE4
May 2021 — Jun 2021 [monthly]

Enrolling By Invitation PHASE4
Jan 2021 — May 2021 [monthly]

Enrolling By Invitation PHASE4
Apr 2020 — Jan 2021 [monthly]

Enrolling By Invitation PHASE4
Feb 2020 — Apr 2020 [monthly]

Enrolling By Invitation PHASE4
Jan 2020 — Feb 2020 [monthly]

Enrolling By Invitation PHASE4
Nov 2019 — Jan 2020 [monthly]

Enrolling By Invitation PHASE4
Oct 2019 — Nov 2019 [monthly]

Enrolling By Invitation PHASE4
Sep 2019 — Oct 2019 [monthly]

Enrolling By Invitation PHASE4
Aug 2019 — Sep 2019 [monthly]

Enrolling By Invitation PHASE4
Jul 2019 — Aug 2019 [monthly]

Enrolling By Invitation PHASE4
Jun 2019 — Jul 2019 [monthly]

Enrolling By Invitation PHASE4
Apr 2019 — Jun 2019 [monthly]

Enrolling By Invitation PHASE4
Mar 2019 — Apr 2019 [monthly]

Enrolling By Invitation PHASE4
Jan 2019 — Mar 2019 [monthly]

Enrolling By Invitation PHASE4
Dec 2018 — Jan 2019 [monthly]

Enrolling By Invitation PHASE4
Nov 2018 — Dec 2018 [monthly]

Enrolling By Invitation PHASE4
Oct 2018 — Nov 2018 [monthly]

Enrolling By Invitation PHASE4

Status: Recruiting → Enrolling By Invitation
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE4
Jul 2018 — Sep 2018 [monthly]

Recruiting PHASE4
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE4
Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE4
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE4
Sep 2017 — Oct 2017 [monthly]

Recruiting PHASE4
Aug 2017 — Sep 2017 [monthly]

Recruiting PHASE4

First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Biotech, Inc., including Johnson & Johnson
Pharmacyclics Switzerland GmbH

Data source: Pharmacyclics Switzerland GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Atlanta, United States , Auckland, New Zealand , Badalona, Spain , Ballarat, Australia , Barcelona, Spain , Bedford Park, Australia , Borås, Sweden , Boston, United States , Box Hill, Australia and 77 more locations